Seeking Alpha
 

Aetna, Inc. (AET)

- NYSE
  • Nov. 20, 2012, 3:34 PM
    Coventry Health (CVH -0.1%) says it plans to hold a special shareholder meeting to consider and vote on proposal to adopt merging Jaguar Merger Subsidiary into Coventry with Coventry continuing as the surviving corporation. The meeting will be held in Nashville, Tennessee on November 21 at 10 am.
    | Comment!
  • Oct. 26, 2012, 6:35 AM
    Coventry Health Care (CVH): Q3 EPS of $0.78 beats by $0.05. Revenue of $3.46B (+16% Y/Y) misses by $40M. (PR)
    | Comment!
  • Oct. 26, 2012, 12:10 AM
    Notable earnings before Friday’s open: ACI, AON, ARLP, AXL, B, CMCSA, CVH, DAN, DLR, EGO, ERIC, GT, HMSY, IMGN, IPG, KKR, LM, LYB, MCO, MRK, OHI, OSK, QSII, TASR, TCB, VTR, WY
    | Comment!
  • Oct. 25, 2012, 5:30 PM
    Notable earnings before Friday’s open: ACI, AON, ARLP, AXL, B, CMCSA, CVH, DAN, DLR, EGO, ERIC, GT, HMSY, IMGN, IPG, KKR, LM, LYB, MCO, MRK, OHI, OSK, QSII, TASR, TCB, VTR, WY
    | Comment!
  • Oct. 25, 2012, 8:50 AM
    More on Aetna (AET) Q3: EPS benefits from heavy buybacks. Profit +1.8% to $499.2M. Earnings boosted by higher premiums, cost cuts and people continuing to avoid the doctor, with the percentage of premiums spent on medical care 80.7% vs 82.4% in Q2. Hits FY target for about 18.2M members, +149K from Q2. Ups FY operating EPS guidance to $5.10 from $5-$5.10 prior estimate and vs $5.08 consensus.
    | Comment!
  • Oct. 25, 2012, 6:01 AM
    Aetna (AET): Q3 EPS of $1.55 beats by $0.21. Revenue of $8.89B (+6% Y/Y) misses by $60M. (PR)
    | Comment!
  • Oct. 25, 2012, 12:05 AM
    Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH
    | Comment!
  • Oct. 24, 2012, 5:30 PM
    Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH
    | 1 Comment
  • Oct. 2, 2012, 9:58 AM
    Around 12M people will buy $55B worth of health coverage in 2014 via the insurance exchanges being created as part of Obamacare, PWC predicts, adding that the figures could rise to 29M people and $205B respectively by 2021. Most of the money will be new, although some will come from other parts of the market, such as from people whose employers had paid for coverage until now.
    | 1 Comment
  • Sep. 30, 2012, 5:51 AM
    Three pension funds that are investors in Coventry Healthcare (CVH) have sued to block its $5.6B acquisitions by Aetna (AET). Among other things, the funds argue that Coventry's shareholders are receiving a premium of just 20%, far less than premiums in other similar deals, which are as much as 43%.
     
    | Comment!
  • Sep. 28, 2012, 3:43 PM
    Dendreon (DNDN +3.8%) bucks a weak tape today after Aetna (AET -0.4%) indicated on its website that it would pay for additional prostate cancer patients to be treated with Provenge, saying it now considers it to be medically necessary for treatment.
    | Comment!
  • Sep. 28, 2012, 3:34 PM
    Aetna (AET) declares $0.175/share quarterly dividend, in line with previous. Forward yield 1.77%. For shareholders of record Oct 11. Payable Oct 26. Ex-div date Oct 09. (PR)
    | Comment!
  • Sep. 21, 2012, 2:38 PM
    Questcor Pharmaceuticals (QCOR +4.5%) continues to recover from Wednesday's dramatic drop of nearly 50%, as Roth Capital joins the chorus of analysts calling the reaction to the Aetna (AET) situation "overblown." QCOR's conference call yesterday "indicated that a highly-engaged and well-prepared reimbursement practice by QCOR has been successful and likely would continue as most cases are tightly sealed and more difficult for denial by insurers." the firm said in a note to clients.
    | Comment!
  • Sep. 20, 2012, 11:38 AM
    More on Questcor (QCOR +8.4%) conference call: COO Steve Cartt says insurance reimbursement for Acthar was already complicated before Aetna's (AET) coverage limitations, but QCOR is experienced in securing coverage for appropriate patients. "We anticipate that insurance coverage for Acthar will continue to be available" for the right patients."
    | Comment!
  • Sep. 19, 2012, 12:35 PM
    Questcor's (QCOR -38.5%) weakness a buying opportunity , says Leerink Swann. The firm says it's confirmed with Aetna (AET -0.3%) that Acthar is reimbursed as a second tier drug, and Acthar sales are still seeing more prescriptions written.
    | 4 Comments
  • Sep. 19, 2012, 10:31 AM
    Questcor (QCOR -34.5%) is getting hammered this morning on another negative report from Citron Research. Citron is saying that Aetna (AET -0.5%) has dropped almost all coverage of QCOR's drug Achtar for treating multiple sclerosis and nephrotic symdrome, saying that studies found no proof of efficacy to substantiate reimbursement. It will, however, continue to provide reimbursement when treating infantile spasms.
    | 4 Comments
Visit Seeking Alpha's
AET vs. ETF Alternatives
Company Description
Aetna Inc. is a health care benefit company, which offers traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans.
Sector: Healthcare
Country: United States